21.4 F
New York
Wednesday, January 12, 2022

Covid-19 Pill Developer to Spend SPAC IPO Funds on Clinical Trial, Hiring

Biopharmaceutical firm Pardes Biosciences plans to spend a large chunk of the funds it raised through a public offering late last month on a pill it is developing to treat -19, including on manufacturing and hiring more clinical staff.Biopharmaceutical firm Pardes Biosciences plans to spend a large chunk of the funds it raised through a public offering late last month on a pill it is developing to treat Covid-19, including on manufacturing and hiring more clinical staff.

Source : WSJ.com: US Business Read More

Related Articles

Leave a Reply

[td_block_social_counter style="style8 td-social-boxed td-social-font-icons" tdc_css="eyJhbGwiOnsibWFyZ2luLWJvdHRvbSI6IjM4IiwiZGlzcGxheSI6IiJ9LCJwb3J0cmFpdCI6eyJtYXJnaW4tYm90dG9tIjoiMzAiLCJkaXNwbGF5IjoiIn0sInBvcnRyYWl0X21heF93aWR0aCI6MTAxOCwicG9ydHJhaXRfbWluX3dpZHRoIjo3Njh9" custom_title="Stay Connected" block_template_id="td_block_template_8" f_header_font_family="712" f_header_font_transform="uppercase" f_header_font_weight="500" f_header_font_size="17" border_color="#dd3333"]
- Advertisement -

Trends Now

- Advertisement -

Latest Articles